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 2 
Abstract 17 
Once released into the environment antibiotics can kill or inhibit the growth of 18 
bacteria, and in turn potentially have effects on bacterial community structure 19 
and ecosystem function. Environmental risk assessment (ERA) seeks to establish 20 
protection limits to minimise chemical impacts on the environment, but recent 21 
evidence suggests that the current regulatory approaches for ERA for antibiotics 22 
may not be adequate for protecting bacteria that have fundamental roles in 23 
ecosystem function. In this study we assess the differences in interspecies 24 
sensitivity of eight species of cyanobacteria to seven antibiotics (cefazolin, 25 
cefotaxime, ampicillin, sufamethazine, sulfadiazine, azithromycin and 26 
erythromycin) with three different modes of action. We found that variability in 27 
the sensitivity to these antibiotics between species was dependent on the mode 28 
of action and varied by up to 70 times for β-lactams. Probabilistic analysis using 29 
species sensitivity distributions suggest that the current predicted no effect 30 
concentration PNEC for the antibiotics may be either over or under protective of 31 
cyanobacteria dependent on the species on which it is based and the mode of 32 
action of the antibiotic; the PNECs derived for the macrolide antibiotics were 33 
over protective but PNECs for β-lactams were generally under protective. For 34 
some geographical locations we identify a significant risk to cyanobacteria 35 
populations based upon measured environmental concentrations of selected 36 
antibiotics.  We conclude that protection limits, as determined according to 37 
current regulatory guidance, may not always be protective and might be better 38 
derived using SSDs and that including toxicity data for a wider range of (cyano-) 39 
bacteria would improve confidence for the ERA of antibiotics.40 
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1. Introduction 45 
Antibiotics are designed to kill or inhibit the growth of bacteria and are 46 
fundamental in the treatment of pathogens in human and veterinary healthcare. 47 
Following their release into the environment however, non-target bacteria may 48 
be affected and the vital ecosystem services they facilitate may be disrupted as a 49 
consequence, which include primary productivity, nutrient cycling and 50 
contaminant degradation (Dopheide et al., 2015; Grenni et al., 2018; Kümmerer, 51 
2009). Aquatic ecosystems are especially at risk due to the concentrations of 52 
antibiotic inputs received from manufacturing plants and hospital effluents, 53 
wastewater treatment plants (WWTP), aquaculture, and run-off from agriculture 54 
(Batt et al., 2007; Brown et al., 2006; Cabello, 2006; Jaimes-Correa et al., 2015; 55 
Larsson, 2014; Larsson et al., 2007; Li et al., 2008; Liu et al., 2017; Watkinson et 56 
al., 2009). The European regulatory environmental risk assessment (ERA) for 57 
antibiotics aims to establish protection limits that prevent “risk of undesirable 58 
effects on the environment” (EC, 2001), but the effectiveness of the current 59 
approach to do so has been questioned (Agerstrand et al., 2015; Brandt et al., 60 
2015; Le Page et al., 2017). In addition, many antibiotics lack data for 61 
environmental bacteria due to the regulatory requirement for ERA testing only 62 
coming into force in 2006; before which most antibiotics had already been 63 
approved (Le Page et al. 2017). Consequently, there is an urgent need to assess 64 
whether the protection limits currently derived according to the current ERA 65 
guideline for antibiotics are able to protect against undesirable effects on the 66 
environment. 67 
 68 
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In the European ERA for human medicinal products and the VICH guidelines for 69 
veterinary antibiotics, protection limits for pharmaceuticals, including 70 
antibiotics, are represented by a predicted no effect concentration (PNEC). This 71 
is calculated by applying an assessment factor (AF) of 10 to the lowest no 72 
observed effect concentration (NOEC) following testing upon a cyanobacteria 73 
(green algae when not an antibiotic), invertebrate, fish and an activated sludge 74 
respiration inhibition test (ASRIT); i.e the PNEC is calculated by dividing the 75 
lowest NOEC by 10. The ASRIT however, is not sensitive to antibiotics 76 
(Kümmerer, 2009; Le Page et al., 2017) and consequently only a single species of 77 
cyanobacteria represents all bacterial diversity in an antibiotic ERA that also 78 
measures a single functional endpoint: primary productivity. Additionally, most 79 
tests use either Anabaena flos-aquae (particularly in the case of regulatory 80 
studies) or Microcystis aeruginosa, providing a limited understanding of 81 
cyanobacteria interspecies sensitivity. In a revised version of the EMA guidance 82 
for ERA that is currently under consultation, however, it is advocated that two 83 
cyanobacteria species should be tested and fish are only tested when the 84 
pharmaceutical targets are present. The AF is applied to account for uncertainty 85 
due to interspecies variability and the extrapolation from controlled laboratory 86 
studies to the field. But the application of an AF of 10 for antibiotics is 87 
unsupported by experimental data and evidence shows that in some cases 88 
interspecies bacterial sensitivity may exceed this by several orders of magnitude 89 
(Chapman et al., 1998; Le Page et al., 2017). Consequently, there may be cases 90 
where the PNEC is not protective of all species in the environment. Moreover, a 91 
PNEC calculated this way has two potential drawbacks: firstly, the NOEC has 92 
been heavily criticised due to its dependence on the design of the experiment 93 
 6 
conducted to derive it (Green et al., 2013) and secondly, because it uses only a 94 
single effect value (the NOEC); quantification of the uncertainty around the PNEC 95 
is not determined (Chapman et al., 1998).  96 
A second approach for establishing protection limits that overcomes some of the 97 
problems associated with the current PNEC approach is through the 98 
construction of a species sensitivity distribution (SSD). A SSD is a probability 99 
model of interspecies variability across a toxicity endpoint following chemical 100 
exposure (e.g. NOEC or ECx) and it allows prediction of the proportion of species 101 
affected at any concentration for the species group modelled (Aldenberg et al., 102 
2001; Belanger et al., 2017; Wheeler et al., 2002). SSDs are more commonly used 103 
for higher tier ERA in plant protection product regulations (EFSA, 2013) or in the 104 
Water Framework Directive (European Commission Joint Research Centre, 105 
2003). The protection limit most often derived from a SSD is the hazardous 106 
concentration that affects no more than 5% of species (HC5), although it has 107 
been suggested that the lower 95% confidence limit of the HC5 (HC52.5%) should 108 
be used to ensure a truly protective limit (Verdonck et al., 2001; Wheeler et al., 109 
2002). This lower, more protective limit, however, will have more statistical 110 
uncertainty. An AF of less than 10 is sometimes applied depending on the 111 
specific regulations and quality/quantity of the data on which the SSD is based 112 
(EFSA, 2013). 113 
In the past SSDs have been criticised for being ecologically unrealistic and for a 114 
lack of statistical robustness but recent advances allow for the mitigation of 115 
some of these concerns (Forbes and Calow, 2002; Kon Kam King et al., 2015; Kon 116 
Kam King et al., 2014). Importantly, SSDs are influenced by the quality and 117 
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number of data included, as well as the choice of taxa, their sensitivity to the 118 
mode of action and the even representation of the taxonomic groups of interest. 119 
Where previously a sample size of 10-15 species was required for a robust 120 
analysis (TGD, 2003), newer protocols that use bootstrap regression and the 121 
incorporation of censored data now allow for the computation of reliable 122 
statistics from a limited dataset (<10 data points) (Kon Kam King et al., 2014; 123 
Wheeler et al., 2002). Fewer species therefore are arguably required to reliably 124 
model the lower tail of the SSD (comprising the most sensitive species) from 125 
which a protection limit could be derived, providing they are all known to be 126 
sensitive to the mode of action (MoA) of the chemical. This is because the SSD 127 
focuses upon the species most at risk and the distribution will not be impacted 128 
by non-sensitive species or taxonomic clades (Schmitt-Jansen et al., 2008; 129 
Segner, 2011). 130 
It is not uncommon for the measured environmental concentrations (MECs) of 131 
antibiotics to exceed the PNEC in the environment, especially in WWTP, hospital 132 
and manufacturing effluents (Batt et al., 2007; Brown et al., 2006; Jaimes-Correa 133 
et al., 2015; Larsson, 2014; Larsson et al., 2007; Li et al., 2008; Watkinson et al., 134 
2009). In these cases it is likely that there is a risk to bacterial communities and 135 
the ecosystem functions that they provide. By considering these MECs in relation 136 
to a SSD it is possible to obtain an indication of the proportion of species that 137 
may be at risk.  138 
In a recent meta-analysis of all publicly available literature we identified that 139 
cyanobacteria sensitivity to antibiotics may vary by up to 100,000 times (Le Page 140 
et al., 2017). For some antibiotics a sensitivity difference exceeding the AF of 10 141 
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occurred between the most sensitive species, most commonly, Microcystis 142 
aeruginosa, and the two species recommended in the OECD 201 test guideline for 143 
establishing protection limits, namely Anabaena flos-aquae and Synechococcus 144 
leopoliensis.  Although in some cases when A. flos-aquae was the most sensitive 145 
species the assessment factor of 10 did appear to be protective. The 146 
aforementioned meta-analysis was based on an assessment of published data 147 
and collated studies performed using different methodologies and test 148 
conditions in different laboratories by different researchers. Accurate 149 
numeration and confidence in relative sensitivities to antibiotic exposure in 150 
cyanobacteria species are best derived through comparative experiments 151 
conducted under the same test design without inter-laboratory variation. 152 
 153 
To this end we optimised a microplate growth inhibition assay to assess the 154 
effects of antibiotic on population growth for eight species of phylogenetically 155 
diverse cyanobacteria (as assessed by their genome sequences (Shih et al., 156 
2013)) culturable under laboratory conditions that are of environmental 157 
relevance (Le Page et al. under review). We focused on cyanobacteria due to 158 
their current key role within ERA and because they are a diverse bacterial clade 159 
of photoautotrophs that are ubiquitous in both aquatic and terrestrial 160 
environments, play key roles in many bacterial communities, and they have a 161 
range of important ecological functions such as primary production and nitrogen 162 
fixation (Falkowski, 1997). 163 
 164 
Seven antibiotics were selected that spanned both a range of antibiotic classes 165 
and modes of action (MoA) in order to assess the impact MoA may have on the 166 
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degree of interspecies sensitivity observed. These included; i) three cell envelope 167 
synthesis inhibiting antibiotics, β-lactams, which target penicillin binding 168 
proteins (which catalyse the building of the peptidoglycan cell membrane of 169 
bacteria) namely, cefazolin and cefotaxime (1st and 3rd generation 170 
cephalosporins, respectively) and ampicillin (a penicillin); ii) two DNA synthesis 171 
inhibitors, sulfadiazine and sulfamethazine (sulfonamides) that prevent the 172 
production of folic acid, a key precursor in the DNA synthesis pathway; and iii) 173 
two protein synthesis inhibitors, erythromycin and azithromycin (macrolides), 174 
which inhibit the normal functioning of the bacterial ribosome. The macrolides, 175 
azithromycin and erythromycin are both candidates to be priority substances in 176 
the EU Water Framework Directive watch list (Carvalho et al., 2015) and US EPA 177 
contaminate list 3 (US EPA, 2009). Cefazolin and sulfamethazine have no 178 
ecotoxicological data available for cyanobacteria in the open literature. 179 
Sulfadiazine, cefotaxime and azithromycin have very limited ERA relevant 180 
ecotoxicological data (Le Page et al., 2017). 181 
 182 
We addressed the hypothesis that current protection limits for antibiotics in 183 
surface water (PNECSW) are not fully protective of all cyanobacteria populations. 184 
We first determined the interspecies sensitivity differences of eight species of 185 
cyanobacteria by performing growth inhibition assays. We then established SSDs 186 
and compared the PNEC calculated according to current guidance with the HC5 187 
and HC52.5% to determine the proportion of species that would be affected 188 
following exposure to the PNEC determined from these results. Finally, based on 189 
our SSDs, we calculated the proportion of cyanobacteria likely to be affected 190 
using published MECs. 191 
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2. Materials and methods 192 
2.1. Test organisms and maintenance 193 
We selected eight cyanobacteria species: Anabaena flos-aquae (CCAP 1403/13A), 194 
Synechococcus leopoliensis (CCAP 1405/1), Anabaena cylindrica (PCC 7122), 195 
Synechococcus elongatus (PCC 6301), Synechococcus sp (PCC 6312), Synechocystis 196 
sp (PCC 6803), Cyanobium gracile (PCC 6307) and Geminocystis herdmanii (PCC 197 
6308). The basis for the selection of each species is given in Supplementary 198 
material A.  199 
 200 
Continuous cultures of exponentially growing cyanobacteria were maintained in 201 
50mL BG-11 medium ((Rippka et al., 1979); using laboratory grade constituents 202 
of >97% purity). Cultures were incubated in Multitron II incubators (Infors) 203 
under test conditions. Cultures were examined visually using an inverted light 204 
microscope to ensure cells appeared healthy before testing. 205 
2.2. Antibiotics 206 
Seven antibiotics were selected: cefozolin sodium salt (CAS: 27164-46-1; purity 207 
≥98%; Tokyo Chemical Industry UK Ltd (TCI)), cefotaxime sodium salt (CAS: 208 
64485-93-4; purity ≥ 91.6%; Sigma-Aldrich), ampicillin trihydrate (CAS: 7177-209 
48-2; purity ≥98%; TCI), sulfadiazine (CAS: 68-35-9; purity ≥99%; Sigma-210 
Aldrich), sulfamethazine (CAS: 57-68-1; purity ≥98%; TCI), azithromycin 211 
dihydrate (CAS: 117772-70-0; purity ≥98%; TCI) and erythromycin (CAS: 114-212 
07-8; purity ≥98%; TCI). These antibiotics span three MoAs that are detailed 213 
above in the introduction.  Additional rationale for their choice was based upon 214 
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one or a combination of the following; i) being a compound of regulatory concern 215 
(Carvalho et al., 2015; US EPA, 2009), ii) having suitable solubility in the test 216 
media, and iii) having limited or no cyanobacteria data available in the literature. 217 
A summary of the chemical properties is given in table 1. 218 
2.3. Growth inhibition assays 219 
Growth rate inhibition assays were performed in 96 well microplates that 220 
followed a procedure adapted from the (Environment Canada, 2007) and (OECD, 221 
2011) test guidelines which was developed as a medium throughput test and 222 
aims to identify which species are susceptible than others and of which the 223 
development and validation is documented in (Le Page et al., under review). 224 
Biomass was measured using phycocyanin fluorescence as a surrogate 225 
(excitation = 590 nm, emission = 650 nm, cut-off = 635 nm; bottom read mode; 226 
Spectromax M5 with Softmax® Pro software (Molecular Devices)). This has been 227 
previously demonstrated to have a linear relationship with cell density for all 228 
species except A. flos-aquae that had a shallower gradient at cell densities below 229 
eight artificial fluorescence units (AFU, Le Page et al., under review). 230 
 231 
A pre-culture for each species was prepared between three and four days prior 232 
to the start of the test in 50 mL of BG-11 under the experimental exposure 233 
conditions (but in the absence of the antibiotic) in order to obtain exponentially 234 
growing cells. A cyanobacteria inoculum was prepared in BG-11 medium at a 235 
phycocyanin fluorescence of 4 AFU (twice the nominal starting inoculum). 236 
Following this a geometric series of stock solutions for each test concentration 237 
were prepared in BG-11 medium at double the nominal test concentrations. 238 
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100μL of test solution was added to 100 μL of cyanobacteria inoculum to achieve 239 
a final cyanobacteria density at 2 AFU at the nominal test concentration in each 240 
well. Assays were conducted in non-transparent, 96 well plates (Greiner Bio-one 241 
item no. 650201), sealed with AMPLIsealTM sealer (Greiner Bio-one item no. 242 
676040) to prevent water loss due to evaporation over the test period. The plate 243 
layout for the incubations described is provided in Supplementary material A. 244 
 245 
The assays were run in Multitron II incubators (Infors) under the following test 246 
conditions: light intensity = 4000 lux, temperature = 28 +/- 1°C and shaking = 247 
140 rpm. The test lengths were optimised to ensure toxicity testing was carried 248 
out, as best as possible, during exponential growth for each species, and these 249 
were: i) 24 hours for the fastest growing species, S. leopoliensis, S. elongates and 250 
Synechococcus sp,; ii) 48 hours for A. flos-aque and Synechocystis sp. The 251 
exception here was for the exposure of the Synechocystis sp. to sulfadiazine 252 
where due to a slower growth rate than expected, an exposure period of 72 253 
hours was adopted; iii) 72 hours for the slower growing species, A. cylindrical, C. 254 
gracile and G. herdmanii. (Le Page et al., under review) provides further 255 
discussion around the selection of exposure times and the potential 256 
consequences for their extension or reduction, although we highlight that with 257 
the current set up we cannot discern the magnitude of effect of the technical 258 
uncertainty caused by comparing several species and how this may impact on 259 
the biological differences observed. 260 
 261 
Daily cell density determinations were made for each well via measurement of 262 
phycocyanin fluorescence. pH was measured in the stocks and in a replicate of 263 
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each test concentration for each species at the end of the test using micro pH 264 
meter (Jenco 6230N; pH probe: Hanna instruments HI1083) to ensure 265 
fluctuations did not exceed the acceptable limits of ±0.2 as defined by most 266 
standardised test guidelines (OECD, 2011). 267 
 268 
For the azithromycin exposure, dimethyl sulfoxide (DMSO) was used as a solvent 269 
carrier at a concentration of 10 μl/L. Ten solvent control replicates were 270 
employed and comparisons of the dilution water control and solvent control 271 
replicates for all species are provided in Supplementary material A. Growth rate 272 
was found not to be significantly different from the dilution water control for any 273 
cyanobacteria with exception of A. flos-aquae and S. elongates where small but 274 
significant decreases in growth rate (p < 0.01) were observed in the solvent 275 
control (two tailed t.test in R, version 3.3.0; R Project for Statistical Computing, 276 
Vienna, Austria). All dose-response curves and subsequent statistical 277 
comparisons with antibiotic exposures were performed using the solvent control 278 
data.  279 
 14 
 280 
Antibiotic 
Primary 
pharmacological 
Target a 
Log 
Kow b 
pKa b 
Log 
Dow 
(pH 8) b 
Solubility 
at pH 8.0 b 
(g/L) 
Cefazolin 
Penicillin 
binding protein 
-1.52 
2.84 (acid)  
0.26 (base) 
-5.04 454.5 
Cefotaxime 
Penicillin 
binding protein 
-1.49 
2.73 (acid)  
3.58 (base) 
-4.24 455.5 
Ampicillin 
Penicillin 
binding protein 
-2 
3.24 (acid)  
7.23 (base) 
-2.72 0.04 
Sulfadiazine 
Dihydropteroate 
synthetase 
-0.39 
6.99 (acid)  
2.01 (base) 
-0.33 8.91 
Sulfamethazine 
Dihydropteroate 
synthetase 
0.65 
6.99 (acid) 
2.00 (base) 
-0.06 4.72 
Azithromycin 
Bacterial 
ribosome 
2.44 
12.43 (acid)  
9.57 (base) 
-0.08 1810 
Erythromycin 
Bacterial 
ribosome 
2.6 
12.45 (acid)   
9 (base) 
1.55 43.3 
Table 1 – Chemical properties of antibiotics.a according to drugbank (www.drugbank.ca). 281 
b predicted by ChemAxon (www.chemicalize.org) 282 
2.4. Chemical analysis 283 
The concentrations of antibiotics in the stocks and in three exposure replicates 284 
for all concentrations and in each species at the end of the tests were measured 285 
using liquid chromatography-mass spectrometry (method supplied in 286 
Supplementary material A). Following the final cell density determination of the 287 
assay, microplates were centrifuged at 4000 rpm for 30 minutes. 150μL of 288 
supernatant was carefully removed and transferred to a deep well microplate 289 
(96-well, 2ml; Porvair Sciences) with acetonitrile (50% volume). Where 290 
necessary samples were further diluted to within the calibration range. All 291 
chemical concentrations are reported as free acids and bases. 292 
In the instances where analytical data was <LOQ or where an extraction error 293 
occurred (see Supplementary material B and Table S.B1) these 294 
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samples/replicates were excluded from further analysis (detailed in Table S.B1) 295 
Limits of quantification (LOQ) for each antibiotic are given in Table S.B2. 296 
2.5. Measured environmental concentrations 297 
The MECs for each antibiotic were obtained from Umweltbundesamt's (UBA) 298 
'Pharmaceuticals in the environment' database (Umwelt bundesamt, 2018). 299 
MECs from all matrices that were measured in, or able to be converted into μg/L 300 
were extracted for use. Measurements of 0 μg/L were removed as they represent 301 
either the absence of the antibiotic or presence below the limit of detection, 302 
which make this analysis assume a worst-case scenario by moving the median to 303 
higher concentrations. MECs from matrixes such as inflows to WWTP, sewage 304 
sludge or untreated hospital and industrial effluents were also removed from the 305 
analysis to leave only environmentally relevant MECs. 306 
2.6. Statistical analysis 307 
2.6.1. Growth rate calculations 308 
Growth rate of cyanobacteria was calculated according to equation below based 309 
on the phycocyanin fluorescence at the start and the end of the assay. 310 
 311 
Growth Rate =
lnΧ𝑗 − lnΧ𝑖
t𝑗 − t𝑖
 312 
where 313 
Xi = cell density at time ti 314 
ti =  i'th time point 315 
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2.6.2. Dose-response modelling and ECx determination 316 
Dose-response curves were fitted in R (version 3.3.0; R Project for Statistical 317 
Computing, Vienna, Austria) using the drc package (Ritz et al., 2015). For all 318 
pairs of bacterial species and antibiotics, growth rate data were fitted to log-319 
logistic (3, 4 and 5 parameters) and Weibull distributions (4 and 5 parameters). 320 
Of these, the optimal distribution was selected based of the log-likelihood score 321 
to represent the data. From this fitted distribution estimates of the 10 and 50% 322 
effective concentrations (ECx) and associated confidence limits were determined. 323 
Data handing for the growth rate determinants for each species are provided in 324 
Supplementary material A. 325 
2.6.3. Species Sensitivity Distributions 326 
SSDs were constructed in R (version 3.3.0; R Project for Statistical Computing, 327 
Vienna, Austria) using the fitdistrplus package (Delignette-Muller and Dutang, 328 
2015) following procedure outlined in the MOSAIC SSD platform (Kon Kam King 329 
et al., 2014). The 95% confidence intervals of the EC10 for each species were used 330 
as interval-censored data (i.e. not a single fixed value but a range between the 331 
95% confidence limits). This allowed for the incorporation of the uncertainty 332 
around the EC10 into the SSD and this increases confidence in the SSD output 333 
(Kon Kam King et al., 2014). Six parametric distributions were fitted to the data: 334 
i) normal, ii) log-normal, iii) Weibull, iv) log-logistic, v) gamma and vi) 335 
exponential. The best fitting distribution was selected based upon a combination 336 
of the Akaike Information Criterion (AIC) score.  337 
The HC5 and associated confidence intervals were determined from 338 
bootstrapping of the data (5000 iterations) based on the parameters of the fitted 339 
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distribution. A similar protocol was followed to derive the SSD, HC5 and 340 
confidence intervals from the NOEC data but for this the NOEC values were used 341 
as non-censored data. 342 
3. Results 343 
3.1. Antibiotic exposure concentrations 344 
The measured concentrations of the antibiotics in each microplate assay, 345 
calculated using a geometric mean of the concentrations at the start (stocks) and 346 
end (exposure replicates) of the test, are provided in the Supplementary material 347 
B (figures S.B1 – S.B14). Overall concentrations of the antibiotics in the test 348 
media varied with losses due, in part, to the presence of the bacteria.  These 349 
losses differed across the various antibiotics tested and species (graphs S.B15 – 350 
S.B21; determined as the difference between concentrations in the wells 351 
containing cyanobacteria and blank replicates (without cyanobacteria)).   352 
 353 
For cefazolin, mean measured concentrations in the exposure replicates ranged 354 
between 14 to 32 % of the nominal concentrations (Fig S.B1). The greatest losses 355 
of cefazolin occurred in the exposures to S. elongates and Synechococcus sp.  356 
 357 
Mean measured concentrations of cefotaxime in the exposure replicates ranged 358 
between 18 and 44% of nominal (Fig S.B3). The greatest reductions in the 359 
exposure replicates compared with replicates without cyanobacteria were for 360 
the Synechococcus genus (Fig S.B16). 361 
 362 
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Mean measured concentrations of ampicillin in the exposure replicates ranged 363 
between 44 and 95% of nominal (Fig S.B5). In the presence of the cyanobacteria 364 
there were generally between 10 and 30% additional reductions compared with 365 
the replicates without bacteria, but was most pronounced in the A. cylindrical 366 
exposure replicates (S.B17). 367 
 368 
Mean measured concentrations of sulfadiazine in the exposure replicates were 369 
between 101 and 142% of nominal (Fig S.B7). The high measured concentrations 370 
of up to 142% of nominal occurred in the nominal 2.36, 145 and 1140 μg/L test 371 
concentrations and they would increase the uncertainty around toxicity 372 
estimates calculated. However, due to the lack of sensitivity of the cyanobacteria 373 
to sulfadiazine (see below) this doesn’t affect any conclusions drawn. Reductions 374 
in sulfadiazine concentrations due to the presence of the cyanobacteria varied 375 
across tests concentrations (S.B18). 376 
 377 
Mean measured concentrations of sulfamethazine in the exposure replicates 378 
ranged between 87 to and 134% of nominal (Fig S.B9). Extraction errors for 379 
nominal concentrations 907 and 1633 μg/L in the S. elongates exposure meant 380 
that these had to be excluded for the analyses.  381 
 382 
Mean measured concentrations of erythromycin in the exposure replicates were 383 
between 71 and 100% of nominal (Fig S.B11) with exception of the nominal 384 
3.77 μg/L test concentration (53% of nominal). Erythromycin concentrations 385 
were lowered by up to 50% over the exposure period and the presence of the 386 
cyanobacteria in the exposure replicates caused additional erythromycin losses 387 
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of on average of 10 and 20% (but up to 60%) compared to replicates without 388 
cyanobacteria present (Fig S.B20).  389 
 390 
Mean measured concentrations of azithromycin in the exposure replicates 391 
ranged between 23 and 79% of nominal (Fig S.B13). Azithromycin 392 
concentrations in the exposure and blank replicates at the end of the exposures 393 
were considerably lower, by up to 96%. The presence of all species of 394 
cyanobacteria had an effect of reducing the test concentrations further by 395 
between 10 and 15% (Fig S.B21). 396 
3.2. Growth inhibition, species sensitivity distributions and protection 397 
limit analysis: 398 
The dose-response curves for growth inhibition of the eight cyanobacteria for 399 
each antibiotic tested are presented in Figure 1. The EC10s, EC50s and NOECs for 400 
the experimental data are given in Table 2 (raw data are provided, and shown 401 
graphically in Supplementary material C, figures S.C1 – S.C7). All dose-response 402 
analyses are based upon geometric mean measured test concentrations. The pHs 403 
at the start and at the end of the tests are provided in Supplementary material D. 404 
 405 
The data in Figure 2 presents the SSDs, based upon cyanobacteria EC10s for each 406 
antibiotic, together with PNECs based upon the NOEC of the most sensitive 407 
species tested (PNEClowest) and the PNECs, based upon the two Organisation for 408 
Economic Co-operation and Development (OECD) test guideline recommended 409 
species (from which all PNECs derived for regulatory purposes are likely derived 410 
from) A. flos-aquae (PNECA. flos-aquae) and S. leopoldensis (PNECS.leopoldensis). SSDs 411 
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based upon cyanobacteria NOECs are provided in Supplementary material C 412 
(figure S.C8).  It was not possible to establish the SSDs for sulfamethazine or for 413 
sulfadiazine as neither produced a full dose response curve from which to 414 
calculate an EC10. 415 
The data in Table 2 provide values for the HC5, PNECs and the proportion of 416 
cyanobacteria affected at these concentrations, predicted from the SSD (based on 417 
the EC10s). Table 3 gives the highest and median MECs and the proportion of 418 
cyanobacteria affected at these concentrations predicted from the SSD (based on 419 
the EC10s). The same information as Tables 2 and 3 are provided in Tables S.C1 420 
and S.C2 but here using the SSD based upon NOEC data.  Table SC.3 provides the 421 
best fitting distributions used for establishing the SSD. 422 
EC10s for the different cyanobacteria exposure for cefazolin ranged between 2.4 423 
and 124 μg/L and the EC50s ranged between 4.1 to 283 μg/L (Figure 1 and Table 424 
1). Based upon both EC10 and EC50 A. flos-aquae and G. herdmanii were the most 425 
sensitive species to cefazolin. Species in the Synechococcus genera (S. leopoliensis, 426 
S. elongates and Synechococcus sp.) along with Synechocystis sp. were the least 427 
sensitive. Synechococcus sp. was up to 70 times less sensitive than the most 428 
sensitive species based on the EC50. The HC5 for cefazolin, based on EC10s, was 429 
1.13 μg/L, which was 7.5 times higher than the lowest PNEC (for A. flos-aquae) 430 
but 4 times lower than that based on S. leopoldensis (Figure 2 and Table 2). The 431 
predicted proportion of cyanobacteria affected at the PNECs ranged between 432 
0.95 and 13.3% depending on which species was used to derive the PNEC (Table 433 
2). The HC5 based on the NOEC data was 5 μg/L, 4 times higher than when based 434 
on the EC10 (Table SC.1). The median MEC was predicted to affect a small fraction 435 
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of cyanobacteria (<1%) based on the SSD. The highest recorded MEC (42.9 μg/L; 436 
the maximum concentration observed in a range of effluents in Taiwan, including 437 
manufacturing and hospital effluents (Lin et al., 2008)) was predicted to affect 438 
60.2% of cyanobacteria (Table 3) with the second highest MEC of 6.2 μg/L 439 
affecting 16.2% of cyanobacteria. The median MEC of 6 hospital effluents in the 440 
same study, of 6.2 μg/L (Lin et al., 2008), would affect 17.3% of cyanobacteria 441 
based on the SSD. 442 
 443 
EC10s for the different cyanobacteria exposure to cefotaxime ranged between 1.2 444 
and 39.8 μg/L and EC50s ranged between 2.2 and 98 μg/L (Figure 1 and Table 1). 445 
The maximum difference in sensitivity (45 times) occurred between A. flos-aquae 446 
(the most sensitive) and Synechococcus sp (the least sensitive). The four least 447 
sensitive species, S. leopoliensis, Synechocystis sp., S. elongates and 448 
Synechococcus sp., were also the least sensitive species to cefazolin, the other 449 
cephalosporin tested, with the same order of relative sensitivity. The HC5 for 450 
cefotaxime, based upon EC10s, was 0.67 μg/L, which was 4 times higher than the 451 
lowest PNEC (for A. cylindrica) and approximately the same value as for the 452 
PNEC based upon S. leopoldensis (Figure 2 and Table 2). The predicted 453 
proportion of cyanobacteria affected at the PNECs ranged between 1.3 and 5.2% 454 
depending on which species was used to derive the PNEC (Table 2). The HC5 455 
based upon the NOEC data was approximately the same as when based on the 456 
EC10 (Table SC.1). The median MEC had little effect upon cyanobacteria based on 457 
the SSD. The highest recorded MEC (41.9 μg/L; the maximum concentration 458 
observed in a range of effluents in Taiwan, including manufacturing and hospital 459 
effluents (Lin et al., 2008)) was predicted to affect 95.9% of cyanobacteria (Table 460 
 22 
3). The median MEC of 6 hospital effluents in the same study, of 0.413 μg/L (Lin 461 
et al., 2008), would affect 3.1% of cyanobacteria based on the SSD. 462 
 463 
EC10s for the different cyanobacteria exposure to ampicillin ranged between 5.9 464 
and 44.6 μg/L and EC50s ranged between 8.4 and 81.4 μg/L (Figure 1 and Table 465 
1). Based on the EC50, there was a difference in sensitivity of approximately 10 466 
times (9.7) between the most sensitive (C. gracile) and least sensitive species 467 
(A. cylindrical). C. gracile was 3 times more sensitive than the next most sensitive 468 
species, S. leopoliensis. The remaining cyanobacteria all had similar sensitivities 469 
with EC50s of between 52 and 81.4 μg/L. The HC5 for ampicillin, based on EC10s, 470 
was 8.6 μg/L, which was 17.5 times higher than the lowest PNEC (for C. gracile) 471 
and 2.9 and 7.4 times higher than the PNECs based on A. flos-aquae and 472 
S. leopoldensis, respectively (Figure 2 and Table 2). The predicted proportion of 473 
cyanobacteria affected at the PNECs ranged between 0.9 and 1.6% depending on 474 
which species was used to derive the PNEC (Table 2). The HC5 based upon the 475 
NOEC data was approximately the same as those based on the EC10 (Table SC.1). 476 
The median MEC indicated little effect upon cyanobacteria based on the SSD. The 477 
highest recorded MEC of 27.1 μg/L (WWTP effluent in India (Mutiyar and Mittal, 478 
2013)) was predicted to affect 44.3% of the cyanobacteria (Table 3). 479 
 480 
Exposure to sulfadiazine only caused partial inhibition of growth of the 481 
cyanobacteria tested (Figure 1). It was possible to fit log-logistic or Weibull 482 
distributions to the growth data but as growth inhibition ceased before the point 483 
of 50% growth inhibition EC10 or EC50 values (and therefore SSDs) could not be 484 
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calculated. The highest recorded MEC was 30.5 μg/L; treated WWTP effluent in 485 
east China (Chen et al., 2012), whilst the median MEC was 0.019 μg/L. 486 
 487 
As for sulfadiazine, sulfamethazine did not induce full growth inhibition for any 488 
of the cyanobacteria tested (Figure 1) preventing the ability to calculate EC10 or 489 
EC50 values (or SSDs). C. gracile was the most sensitive species to the growth 490 
inhibition effects of sulfamethazine (a 50% reduction in growth rate was 491 
observed at an exposure concentration of 1465 μg/L). At the highest tested 492 
exposure concentration (10,000 μg/L) there was between a 30% and 40% 493 
decrease in growth rate in A. flos-aquae, A. cylindrical, S. leopoliensis, S. elongates, 494 
Synechococcus sp., and G. herdmanii. Synechocystis sp was far less affected with 495 
only a 4% inhibition of growth at the highest tested concentration. The highest 496 
recorded MEC was 25.4 μg/L; treated WWTP effluent in Korea (Sim et al., 2011), 497 
whilst the median MEC was 0.015 μg/L. 498 
 499 
EC10s for the different cyanobacteria exposure to erythromycin ranged between 500 
21.1 and 58.8 μg/L and the EC50s were between 43.4 and 135.1 μg/L (Figure 1 501 
and Table 1). Based upon the EC50, there was only a small interspecies difference 502 
in sensitivity; 3.1 times, between the most sensitive (A. cylindrical) and least 503 
sensitive species (A. flos-aquae). The HC5 for erythromycin, based upon EC10s, 504 
was 21.3 μg/L, which was 34.4 times higher than the lowest PNEC (for 505 
S. elongatus) and 7.3 and 6.9 times higher than the PNECs for A. flos-aquae and 506 
S. leopoldensis, respectively (Figure 2 and Table 2). The proportion of 507 
cyanobacteria affected at the PNECs was <1% for all PNECs irrespective of which 508 
species was used to derive it (Table 2). The HC5 based upon the NOEC data was 509 
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3.5 times lower than when based on the EC10 (Table SC.2). No species of 510 
cyanobacteria are predicted to be affected by the MECs based on the SSD 511 
(highest MEC was 7.8 μg/L; untreated manufacturing discharge in China (Lin and 512 
Tsai, 2009)) (Table 3).  The HC5 in this study was 107 times higher (HC52.5 was 513 
81 times higher) than the PNEC in the European Unions watch list of priority 514 
substances for erythromycin is 0.2 μg/L (Loos et al., 2018), but a PNEC based 515 
upon the lowest NOEC, based on S. elongates, would have been only <3 times 516 
higher (NOEC <0.62 μg/L). 517 
 518 
EC10s for the different cyanobacteria exposure to azithromycin ranged between 519 
3.2 and 17.7 μg/L and EC50s ranged between 5.4 and 33.8 μg/L (Figure 1 and 520 
Table 1). Based upon the EC50, there was difference in sensitivity of 6.3 times 521 
only between the most sensitive (A. cylindrical) and least sensitive species 522 
(Synechococcus sp.). The HC5 for azithromycin, based on EC10s, was 3.2 μg/L, 523 
which was 21 times higher than the lowest PNEC (for G. herdmanii) and 3.1 and 524 
16.6 times higher than the PNECs for A. flos-aquae and S. leopoldensis, 525 
respectively (Figure 2 and Table 2). The predicted proportion of cyanobacteria 526 
affected at the PNECs was <1% for all PNECs irrespective of which species was 527 
used to derive it (Table 2). The HC5 based upon the NOEC data was 528 
approximately half as much as when based on the EC10 (Table SC.2). The median 529 
MEC had no effect upon cyanobacteria based on the SSD, whilst the highest 530 
recorded MEC of 2.8 μg/L (from a WWTP in Las Vegas; (Jones-Lepp et al., 2012)) 531 
was predicted to affect 3% of cyanobacteria (Table 3). The HC5 in this study was 532 
166 times higher (HC52.5 was 111 times higher) than the PNEC in the European 533 
Unions watch list of priority substances for azithromycin, 0.019 μg/L (Loos et al., 534 
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2018), but a PNEC based upon the lowest NOEC, based on G. herdmenii, would 535 
have been only <8 times higher (NOEC = 0.15 μg/L).  536 
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 537 
Figure 1 – Fitted concentration - response curves showing the effects of antibiotics on the growth 538 
rate of cyanobacteria. Curves are based upon 10 exposure concentrations Antibiotics are 539 
arranged (vertical panels) according to their mode of action. Red dotted line indicates the highest 540 
measured environmental concentration (MEC) in UBA database (Umwelt bundesamt, 2018). Raw 541 
data plots are presented in Supplementary material C. In some cases the number of 542 
concentrations tested falling on the slope of the dose response curve may be low (< 3) and this 543 
may influence the confidence (robustness) of  the toxicity estimation.  544 
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Antibiotic Species 
EC10 
estimate 
(μg/L) 
EC10 
Low CL 
(μg/L) 
EC10 
High CL 
(μg/L) 
EC50 
estimate 
(μg/L) 
EC50 
Low CL 
(μg/L) 
EC50 
High CL 
(μg/L) 
NOEC 
(μg/L) 
Difference in 
sensitivity a 
Cefazolin 
A. flos-aquae 2.4 1.7 3.0 4.1 3.7 4.5 1.5 
70 
A. cylindrical  7.9 2.9 12.8 17.8 15.4 20.2 6.4 
C. gracile  32.2 24.8 39.5 51.3 47.5 55.1 44.0 
G. herdmanii  3.1 2.6 3.5 5.1 4.8 5.3 4.5 
S. elongates  111.3 97.3 125.3 238.0 217.6 258.3 66.4 
S. leopoliensis 51.6 41.4 61.9 134.1 122.5 145.6 45.3 
Synechococcus sp 124.1 101.5 146.8 283.2 263.6 302.8 93.4 
Synechocystis sp 104.5 80.9 128.1 191.3 170.0 212.5 157.0 
Cefotaxime 
A. flos-aquae 1.4 1.0 1.8 2.2 2.0 2.4 1.9 
45 
A. cylindrical  1.2 0.3 2.2 3.1 2.2 4.1 1.7 
C. gracile  8.3 7.5 9.2 15.4 14.8 16.0 9.6 
G. herdmanii  15.1 8.9 21.4 17.7 14.7 20.6 9.9 
S. elongates  20.8 16.2 25.4 75.4 56.3 94.4 12.7 
S. leopoliensis 8.7 7.0 10.3 31.0 28.7 33.3 7.0 
Synechococcus sp 16.2 11.5 20.8 97.9 74.2 121.6 12.1 
Synechocystis sp 39.8 28.3 51.3 62.3 53.7 71.0 46.3 
Ampicillin 
A. flos-aquae 18.7 11.6 25.9 52.4 45.2 59.7 30.2 
9.7 
A. cylindrical  44.6 40.0 49.3 81.4 73.5 89.2 37.1 
C. gracile  5.9 5.1 6.7 8.4 7.4 9.4 4.9 
G. herdmanii  34.3 27.2 41.4 64.4 60.5 68.3 12.2 
S. elongates  38.8 35.0 42.7 54.0 50.4 57.6 36.4 
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Antibiotic Species 
EC10 
estimate 
(μg/L) 
EC10 
Low CL 
(μg/L) 
EC10 
High CL 
(μg/L) 
EC50 
estimate 
(μg/L) 
EC50 
Low CL 
(μg/L) 
EC50 
High CL 
(μg/L) 
NOEC 
(μg/L) 
Difference in 
sensitivity a 
S. leopoliensis 16.2 11.8 20.6 27.5 25.1 29.9 11.5 
Synechococcus sp 38.0 30.1 45.9 66.6 63.0 70.1 31.5 
Synechocystis sp 36.5 25.8 47.2 57.1 50.7 63.5 34.2 
Sufadiazine 
A. flos-aquae N/A N/A N/A N/A N/A N/A N/A 
N/A 
A. cylindrical  N/A N/A N/A N/A N/A N/A N/A 
C. gracile  N/A N/A N/A N/A N/A N/A N/A 
G. herdmanii  N/A N/A N/A N/A N/A N/A N/A 
S. elongates  N/A N/A N/A N/A N/A N/A N/A 
S. leopoliensis N/A N/A N/A N/A N/A N/A N/A 
Synechococcus sp N/A N/A N/A N/A N/A N/A N/A 
Synechocystis sp N/A N/A N/A 1275 1058 1493 380 
Sulfamethazine 
A. flos-aquae N/A N/A N/A N/A N/A N/A N/A 
N/A 
A. cylindrical  N/A N/A N/A N/A N/A N/A N/A 
C. gracile  N/A N/A N/A N/A N/A N/A N/A 
G. herdmanii  N/A N/A N/A N/A N/A N/A N/A 
S. elongates  N/A N/A N/A N/A N/A N/A N/A 
S. leopoliensis N/A N/A N/A N/A N/A N/A N/A 
Synechococcus sp N/A N/A N/A N/A N/A N/A N/A 
Synechocystis sp N/A N/A N/A N/A N/A N/A N/A 
Azithromycin 
A. flos-aquae 10.5 7.1 14.0 25.8 22.4 29.3 10.2 
6.3 A. cylindrical  5.0 3.8 6.2 5.4 0.6 10.1 4.9 
C. gracile  4.8 3.8 5.7 12.5 10.3 14.6 9.5 
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Antibiotic Species 
EC10 
estimate 
(μg/L) 
EC10 
Low CL 
(μg/L) 
EC10 
High CL 
(μg/L) 
EC50 
estimate 
(μg/L) 
EC50 
Low CL 
(μg/L) 
EC50 
High CL 
(μg/L) 
NOEC 
(μg/L) 
Difference in 
sensitivity a 
G. herdmanii  3.2 2.2 4.3 13.8 11.8 15.8 1.5 
S. elongates  4.4 2.7 6.0 17.4 14.9 19.9 3.3 
S. leopoliensis 8.7 6.7 10.6 23.5 21.6 25.4 1.9 
Synechococcus sp 17.7 13.5 21.9 33.8 31.5 36.1 2.6 
Synechocystis sp 8.6 5.7 11.4 18.1 12.9 23.4 9.6 
Erythromycin 
A. flos-aquae 58.8 41.5 76.1 135.1 121.9 148.3 28.8 
3.1 
A. cylindrical  22.3 16.5 28.2 43.9 40.2 47.6 12.2 
C. gracile  44.5 15.5 73.5 57.3 56.0 58.6 31.2 
G. herdmanii  50.7 42.6 58.7 104.8 98.1 111.5 11.5 
S. elongates  30.1 26.4 33.9 63.3 57.7 68.9 <6.2 
S. leopoliensis 35.0 28.6 41.3 63.9 53.6 74.1 31 
Synechococcus sp 29.1 23.8 34.4 59.8 55.6 64.0 13.4 
Synechocystis sp 21.2 12.3 30.1 55.7 49.5 61.8 <7.2 
Table 2 – Antibiotic 10% and 50% effective concentrations (ECx) and no observed effect concentrations (NOEC) for growth inhibition of eight cyanobacteria 546 
species. All concentrations are reported in μg/L. CL = Confidence Limit. a Times difference calculated by largest ECx/smallest ECx – reported value is based on 547 
largest range of EC10 and EC50. Mode of Actions: cefazolin , cefotaxime amd ampicillin are cell membrane synthesis inhibitors; sufadiazine and sulfamethazine are 548 
DNA synthesis inhibitors (Anti-folates); Azithromycin and Erythromycin are Protein synthesis inhibitors. 549 
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 550 
Figure 2. Species sensitivity distributions of cyanobacteria exposed to five antibiotics; cefazolin and cefotaxime (cephalosporins), ampicillin (penicillin), 551 
azithromycin and erythromycin (macrolides). Red line indicates the modelled species sensitivity distribution. Dashed black lines represent upper and lower 95% 552 
confidence limits. Blue shaded area indicates results of bootstrapped distributions. Orange coloured vertical lines indicate predicted no effect concentrations 553 
(PNEC): Dot-dash orange line= PNEClowest; Dashed orange line = PNECA. flos-aquae; Dotted orange line = PNECS. leopoldensis.554 
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Antibiotic 
Protection 
limit 
Concentration 
(μg/L) 
Lower 95% CI Higher 95% CI 
Proportion of 
cyanobacteria 
affected (%) 
Cefazolin 
HC5 1.13 0.13 19.88 5 
PNECLowest 0.15 - - 0.95 
PNECA. flos-aquae 0.15 - - 0.95 
PNECS. leopoldensis 4.53 - - 13.26 
Cefotaxime 
HC5 0.67 0.32 1.13 5 
PNECLowest 0.17 - - 1.29 
PNECA. flos-aquae 0.19 - - 1.44 
PNECS. leopoldensis 0.7 - - 5.2 
Ampicillin 
HC5 8.56 0** 26.47 5 
PNECLowest 0.49 - - 0.91 
PNECA. flos-aquae 3 - - 1.56 
PNECS. leopoldensis 1.15 - - 1.05 
Erythromycin 
HC5 21.3 16.18 28.76 5 
PNECLowest 0.62 * - - 0 
PNECA. flos-aquae 2.9 - - 0 
PNECS. leopoldensis 3.1 - - 0 
Azithromycin 
HC5 3.15 2.11 5.03 5 
PNECLowest 0.15 * - - 0 
PNECA. flos-aquae 1.02 - - 0 
PNECS. leopoldensis 0.19 - - 0 
Table 2. Protection limits; 5% hazardous concentration (HC5) based upon a species sensitivity 555 
distribution (SSD) using 10% effective concentrations (EC10), predicted no effect concentrations 556 
(PNECs) and the proportion of cyanobacteria affected based upon the SSD. PNECs determined as 557 
specified in current environmental risk assessment. PNECLowest represents the PNEC based on the 558 
most sensitive cyanobacteria in the conducted assays. PNECA. flos-aquae and PNECS. leopoldensis are 559 
based on the data of species recommended in the OECD 201 test guideline (OECD, 2011). 560 
* PNECLowest for erythromycin is < 0.62 and < 0.15 for azithromycin. ** CI was determined to be 561 
<0.  562 
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 563 
Antibiotic 
Measured 
concentration 
Concentration (μg/L) 
Proportion of 
cyanobacteria 
affected (%) 
Cefazolin 
Median 0.15 (10) 0.95 
Highest 42.9 (Lin et al., 2008) 60 
Cefotaxime 
Median 0.033 (16) 0.25 
Highest 41.9 (Lin et al., 2008) 96 
Ampicillin 
Median 0.021 (15) 0.85 
Highest 27.1 (Mutiyar and Mittal, 2013) 44 
Erythromycin 
Median 0.050 (533) 0 
Highest 7.8  (Lin and Tsai, 2009) 0 
Azithromycin 
Median 0.054 (255) 0 
Highest 2.8 (Jones-Lepp et al., 2012) 3 
Table 3. Proportion (%) of cyanobacteria affected at median and highest measured environmental 564 
concentrations (MECs) based on the cyanobacteria species sensitivity distributions using 10% 565 
effective concentrations and MECs obtained from Umweltbundesamt's 'Pharmaceuticals in the 566 
environment' database (Umwelt bundesamt, 2018). Bracketed numbers indicate number of MECs 567 
in median calculation. 568 
4. Discussion 569 
We show that for eight species of cyanobacteria the sensitivity for growth 570 
inhibition for antibiotic exposure can vary widely and is influenced by the 571 
antibiotic MoA. For the β-lactam antibiotics in particular, the interspecies 572 
sensitivity varied by up to 70 times, far exceeding the AF of 10 currently applied 573 
to the NOEC to establish the PNEC in ERA (based on a single species of 574 
cyanobacteria). The SSD analysis indicated however that the current regulatory 575 
approach to ERA in Europe was generally protective of >98% of cyanobacteria 576 
populations when the reference test species employed for this was A. flos-aque. 577 
In contrast, the PNECs derived for cefazolin and cefotaxime when testing was 578 
based upon S. leopoldensis (another OECD recommended species) would result in 579 
growth inhibition for 13% and 5% of the tested cyanobacteria, respectively. In 580 
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the case of macrolides, the SSDs showed that an AF of 10 might be at a level that 581 
is suitable for the adequate population protection of cyanobacteria. We show 582 
that in some of the more polluted environments with antibiotics, based on the 583 
highest published MECs in the literature, up to 60% of cyanobacteria populations 584 
may be affected in these specific environments.  585 
4.1. Chemical analysis, fate and behavior in the cultures 586 
Our analytical results showed considerable variation in the fate of the antibiotics 587 
in our assays. Generally speaking, reductions in the measured concentrations 588 
over the exposure period were high for the β-lactams, likely due to 589 
photodegradation (Wang and Lin, 2012 {Arsand, 2018 #177), and for 590 
azithromycin possibly due to adsorption to the culture vessel materials and 591 
cellular or extracellular matter given its high partition-coefficient (LogP, 4.02) 592 
and adsorption coefficient (Kd, 3100) (National Center for Biotechnology 593 
Information, 2018). Erythromycin and the sulfonamides were more stable in the 594 
assay system. 595 
 596 
Generally, the presence of the cyanobacteria resulted in a reduced amount of 597 
antibiotic in the culture medium (measured at the end of the exposure) likely as 598 
a consequence of adsorption and/or uptake into the bacterial cells and/or 599 
biodegradation by the cyanobacteria. Biodegradation is considered the most 600 
likely factor influencing the measured levels between the species studied for any 601 
one antibiotic, particularly notable in the β-lactams, as differences in surface 602 
binding of the antibiotic alone are very unlikely to account for this variation. 603 
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Further discussion on the fate of the antibiotics tested in the assays can be found 604 
in Supplementary material B. 605 
4.2. Cyanobacteria sensitivity 606 
β-lactams: There was a major difference (up to 70 times) in sensitivity to β-607 
lactams (and in particular the cephalosporins) between the different species of 608 
cyanobacteria in our study. The reason for this is unknown but it may reflect 609 
differences in uptake rates caused by the quantity and type of porins in the outer 610 
membrane (Li et al., 2015; Sugawara et al., 2016). The bilayered outer 611 
membrane of cyanobacteria (and Gram-negative bacteria) is comprised of a 612 
hydrophobic lipopolysaccharide and acts as an effective barrier to most drugs. 613 
Antibiotics must therefore permeate through the membrane or use porin 614 
channels to enter the periplasm. Porins tend to let small and non-lipophilic 615 
molecules pass through with ease, which includes the β-lactams (as well as 616 
fluoroquinolones, tetracycline, chloramphenicol, cycloserine, and 617 
aminoglycosides antibiotics) (Delcour, 2009; Li et al., 2015). For the relatively 618 
small molecules of cefazolin and ampicillin, we might thus expect that porin 619 
channels to be the uptake main route. For the larger antibiotic cefotaxime 620 
however, diffusion through the outer membrane may be more important in 621 
cellular uptake as it may be too large to easily pass through porins.  Indeed, the 622 
susceptibility of the Gram-negative bacteria, K. pneumonia, was 4-8 times higher 623 
to cefotaxime when the strain expressed a larger porin channel (García-Sureda et 624 
al., 2011). 625 
 626 
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Porins differ between bacterial clades and cyanobacteria specifically do not 627 
appear to have the same porin families as those typically found in other bacteria 628 
(Flores et al., 2006). Gram-negative bacteria, for example, generally have smaller 629 
outer membrane porins but with higher channel conductance than cyanobacteria 630 
allowing more molecules to enter into the cell (Hoiczyk and Hansel, 2000). It is 631 
hypothesised that, as autotrophs, cyanobacteria synthesise the large organic 632 
molecules they require (Hoiczyk and Hansel, 2000; Kowata et al., 2017), whilst 633 
non-autotrophic bacteria need to uptake more (and larger) molecule types from 634 
outside of the cell. It is therefore reasonable to hypothesise that cyanobacteria 635 
may not be as susceptible as Gram-negative bacteria to larger antibiotics that 636 
require larger porin channels. Since ERA only uses one species of cyanobacteria 637 
to represent all primary producer diversity, if sensitivity is, at least in part, 638 
driven by uptake due to their outer membrane porins, other bacterial clades 639 
such as Gram-negative bacteria that differ in their membrane structure and 640 
porins may not be well represented.  641 
 642 
In addition to uptake, efflux and β-lactamase enzymes may have key roles in 643 
determining the sensitivity of bacteria to antibiotics. Efflux rates of the 644 
antibiotics in cyanobacteria studied are not known and thus conclusions cannot 645 
be drawn, but our data do indicate the possibility of biodegradation for all the β-646 
lactams tested. For cefazolin this (potential) biodegradation was greatest for 647 
S. elongates and Synechococcus sp., which were also the least sensitive species 648 
tested based on growth inhibition. This is in accordance with findings that the 649 
Gram-negative Enterobacteriaceae family showed interspecies variability in 650 
sensitivity to β-lactams, ranging by between one and two orders of magnitude, 651 
 36 
which were attributed to differences in chromosomal β-lactamases (Stock, 652 
2005). 653 
 654 
Sulphonamides: Growth inhibition of cyanobacteria following exposure to 655 
sulfonamides was generally limited and in some species the inhibitory effect 656 
plateaued with increasing antibiotic concentration, which may suggest the 657 
initiation of a possible resistance mechanism. The results are in accordance with 658 
a recent meta-analysis where cyanobacteria were found to be less sensitive to 659 
sulfonamides compared to microalgae and macrophytes (Le Page et al., 2017). A 660 
possible explanation for their insensitivity could be that cyanobacteria contain a 661 
protein (slr0642 identified in Synechocystis) that may act as a folate transporter 662 
and which allows the uptake of folates from the environment. This in turn 663 
overcomes the effect of the targeting of this drug on the folate synthesis pathway 664 
(de Crécy-Lagard et al., 2007; Klaus et al., 2005). It should be highlighted that the 665 
growth rate was lower than the controls and thus there appears to be some 666 
fitness consequence to this resistance mechanism. 667 
 668 
Macrolides: Responses to the macrolides were more consistent across the 669 
cyanobacteria compared with the β-lactam antibiotics; the EC10s and EC50s for 670 
the eight species differed by less than an order of magnitude.  Uptake and efflux 671 
may also influence the differences in cyanobacteria sensitivity to macrolides. 672 
Indeed, (Stock, 2005) hypothesized that Gram-negative bacteria species specific 673 
differences are, at least in part, driven by differences in outer membrane 674 
hydrophobicity. Due to macrolides large size, uptake is generally thought to be 675 
restricted by the outer membrane (Delcour, 2009; Stock, 2005), although there is 676 
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some evidence that porin-like uptake may be present (Hahn et al., 2012). 677 
Azithromycin is dicationic and less hydrophobic than erythromycin and may 678 
therefore pass through the outer membrane more easily (Farmer et al., 1992; 679 
Stock, 2005).  680 
 681 
The similar levels of efficacy of the macrolides across the different cyanobacteria 682 
species may, in part, be explained by the highly conserved ribosome drug target 683 
(Lecompte et al., 2002; Yutin et al., 2012). R-proteins however, which make up 684 
the ribosome, do vary between broader bacterial taxonomic clades and because 685 
the MoA of macrolide antibiotics is highly dependent on the positioning and 686 
interaction with the ribosome, differences in r-proteins between bacterial taxa 687 
could feasibly affect antibiotic efficacy/action. Based on the literature, therefore, 688 
the differences in cyanobacterial sensitivity to macrolides are more likely to 689 
driven by differences in uptake or efflux than differences in the drug target given 690 
that their ribosomes are likely evolutionarily well conserved. In addition to 691 
decreased uptake/increased efflux, other mechanisms of resistance to 692 
macrolides in Gram-negative bacteria comprise target mutations, methylation, 693 
pseudouridylation and modification of the macrolide (Gomes et al., 2017), but 694 
such resistance mechanisms have not yet been considered in cyanobacteria. 695 
 696 
In our assays azithromycin had a greater potency than erythromycin across all 697 
cyanobacteria species. Interestingly, azithromycin is reported to have modes of 698 
action in addition to the ribosomal drug target that may help to explain this 699 
enhanced potency. It is dicationic and it may disrupt the outer bacterial 700 
membrane through the displacement of divalent cations from their binding sites 701 
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on adjacent lipopolysaccharide molecules in Gram-negative bacteria (Farmer et 702 
al., 1992; Imamura et al., 2005).  703 
4.3. Sensitivity comparisons with other bacteria 704 
Due to the limited data available for environmental bacteria we have compared 705 
the MIC for clinically relevant bacteria with the data obtained in our assays, but 706 
these values represent different parts of the dose-response curve (the MIC 707 
represents the concentration with complete inhibition and the EC10 the 708 
concentration that inhibits growth rate by 10%) (Bengtsson-Palme and Larsson, 709 
2018; Le Page et al., 2018). Additionally, the EUCAST data is not based on 710 
measured concentrations and since the tests are conducted in the dark, we might 711 
thus expect less degradation via photolysis than observed in our assays. 712 
 713 
When comparing the effects of β-lactams in this study with the MICs of clinically 714 
relevant bacteria in the EUCAST database, the most sensitive cyanobacteria in 715 
our study were 3-6 times more sensitive to cefozolin. In accordance with our 716 
hypothesis above that cyanobacteria may be less sensitive to the larger 717 
antibiotics as they do not have porins that enable their uptake, several of the 718 
clinically relevant bacteria appeared to be more sensitive to cefotaxime than 719 
cyanobacteria (EUCAST). The effects of ampicillin on the cyanobacteria were 720 
similar to those observed on cyanobacteria by (Ando et al., 2007) and within the 721 
ranges seen in clinically relevant bacteria in the EUCAST database (EUCAST).  722 
 723 
There are limited published data available for sulfadiazine and sulfamethazine. 724 
They are both veterinary antibiotics and so neither have EUCAST data and their 725 
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ecotoxicological profiles are rather poorly understood. Investigators have found 726 
however that the MICs for sulfamethazine tend to be relatively high (>512 mg/L 727 
for both Gram-negative and Gram positive bacterial strains) compared with 728 
other antibiotics (Salmon and Watts, 2000; Salmon et al., 1995).  729 
 730 
Data on azithromycin is limited for ecotoxicologically relevant species but our 731 
results are in accordance with those reported in (Vestel et al., 2015) where 732 
cyanobacteria (species not provided) had a EC50 of 1.8 μg/L. The MICs of 733 
clinically relevant bacteria in the EUCAST database suggest that growth in the 734 
most sensitive bacteria is inhibited completely at 16 μg/L, which is consistent 735 
with that for the more sensitive cyanobacteria in this study. For erythromycin, 736 
EC50s were generally similar to those obtained for eight species of cyanobacteria 737 
by (Ando et al., 2007). They similarly found, A. cylindrical, to be the most 738 
sensitive species but calculated the EC50s to be over an order of magnitude lower 739 
than in this study (3.5 compared to 44 μg/L respectively), albeit their tests 740 
exposure period was twice that of in this study (6 days) (Ando et al., 2007)). The 741 
most sensitive clinically relevant bacteria to erythromycin in the EUCAST 742 
database have MICs from 8 μg/L (EUCAST), suggesting that for this antibiotic 743 
that clinically relevant bacteria may be more sensitive than cyanobacteria. 744 
4.4. Implications for ERA 745 
4.4.1. PNECs with an assessment factor of 10 are not always protective 746 
Our data suggest that for the β-lactams, depending on which species the PNEC 747 
was derived from, protection of >95% of cyanobacteria species was not be 748 
predicted by our SSDs, even with an assessment factor of 10 applied to account 749 
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for such interspecies sensitivity differences. For the two macrolides however, the 750 
PNEC was protective of all cyanobacteria regardless of the species from which 751 
the PNEC was derived. These data indicate that under current ERA procedures 752 
(of using a single test species) the choice of species is critical in establishing a 753 
protection limit and the MoA can be an important factor in this consideration. 754 
The large interspecies variability observed between cyanobacteria exposed to 755 
cell membrane synthesis inhibitors causes the PNEC to have a higher probability 756 
of being under protective because the assessment factor of 10 is likely 757 
inadequate as highlighted in our previous meta-analysis (Le Page et al., 2017). 758 
For other MoAs, such as the macrolides, the smaller interspecies variability 759 
means an assessment factor of 10 is sufficient to cover the entire SSD no matter 760 
which species is selected on which to base the PNEC.  761 
The limited sensitivity of cyanobacteria to sulfonamide antibiotics confirmed the 762 
findings from the previous meta-analysis (Le Page et al., 2017) expressing 763 
concern that cyanobacteria may not be suitable for the estimation of 764 
environmental protection limits. Furthermore, in some cases microalgae and 765 
macrophytes may be more sensitive than cyanobacteria to this class of 766 
antibiotics (Le Page et al., 2017) but under current ERA framework for 767 
pharmaceuticals neither microalgae nor macrophytes would be tested, although 768 
the revised ERA currently under consultation for the European Medicine Agency 769 
does require a microalgae in addition to two cyanobacteria species and an 770 
invertebrate (EMA, 2018). 771 
 772 
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4.4.2. The HC5 may provide a better protection limit than the traditional 773 
PNEC 774 
Results from this analysis suggest that an approach using a SSD with eight 775 
cyanobacteria to derive an HC5 or HC5(2.5) with a small assessment factor (of less 776 
than 10) may be more suitable for the determination of protection limits for 777 
cyanobacteria populations than the traditional PNEC. But additional testing on 778 
other bacterial classes is required to ensure protection of bacteria more 779 
generally.  We emphasise that a PNEC based on the NOEC and AF of 10 was 780 
generally adequately protective providing the species on which it was based was 781 
sensitive. If we consider the two species recommended in the OECD 201 test 782 
guideline, a PNEC based upon A. flos-aquae was protective but a PNEC based 783 
upon S. leopoldensis was under protective for both cefazolin and cefotaxime. 784 
Furthermore, for some MoAs such as sulphonamides, its possible that a PNEC 785 
using an AF of 10 will be under protective of bacteria more generally regardless 786 
of which cyanobacteria species is used.  787 
For the cephalosporins, the HC5 was generally 4 - 8 times higher than the 788 
PNEClowest but the HC5(2.5%) was more similar at 0.9 - 2 times higher. For the 789 
macrolides the HC5 far exceeded this and was up to 34 times higher than the 790 
PNEClowest, further highlighting how the PNEC and assessment factor of 10 might 791 
be highly conservative as a protective factor for this antibiotic class/MoA. These 792 
results therefore support the suggestion that the HC5(2.5%) could be used to 793 
ensure an empirically based protection limit that is a more accurate and is 794 
protective of 95% of cyanobacteria (Wheeler et al., 2002) without being over 795 
protective in for some MoAs as appears to be the case for the PNECs for 796 
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macrolides. The HC5 95% confidence intervals suggest some uncertainty 797 
(although this is relatively small) but given that these estimates incorporate the 798 
error around the original EC10s via the use of the 95% confidence limits as 799 
censored data, this might be expected. The wider HC5 95% confidence limits for 800 
cefazolin may be due to higher variability observed between replicates in the 801 
microplate assay.  802 
The HC5 has been suggested as a protection limit under the premise that 803 
functional redundancy (where multiple species are capable of performing the 804 
same ecological functions) in the ecosystem will compensate for some small 805 
effects on the most sensitive species (Solomon and Sibley, 2002). However, the 806 
magnitude of functional redundancy is not clear, especially in bacterial 807 
communities (Antwis et al., 2017). Further investigation is required to explore 808 
the hypothesis that 5% of species can be affected beyond their EC10 without 809 
adverse effects upon environmental communities and ecosystem function. Such 810 
studies are best undertaken using semi-field test designs, as conducted, for 811 
example, by (Rico et al., 2014). These authors found disruptions to the nitrogen 812 
cycle occurred in mesocoms exposed to enrofloxacin that resulted from reduced 813 
numbers of ammonia-oxidising bacteria and archaea leading to higher ammonia 814 
and lower nitrate concentrations.  In order to better estimate the effects of 815 
antibiotics on ecosystem functioning, additional endpoints that better represent 816 
functions of interest might usefully be included, for example oxygen evolution 817 
(as a proxy for photosynthetic rate) and pigment content (Guo et al., 2016b).  818 
The selection of species for use in an SSD is important (Verdonck et al., 2003). 819 
Our analysis reflects only cyanobacteria sensitivity, and even here we studied 820 
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only a small selection of classes of cyanobacteria that grew adequately in the 821 
assay method adopted. Thus, a more diverse range of bacteria should be 822 
included since sensitivity differences between taxonomic clades could be large, 823 
even spanning several orders of magnitude. Furthermore, it should be 824 
emphasised that non-bacterial taxa including certain macrophytes (Le Page et al., 825 
2017) and diatoms (Guo et al., 2016a) have been shown to be more sensitive to 826 
some antibiotics (e.g. sulphonamides and trimethoprim) than cyanobacteria. It is 827 
likely that some other bacterial taxa (i.e. not cyanobacteria) could be equally or 828 
more sensitive than all eukaryotes and thus it should be possible to select an 829 
appropriate diversity of bacteria for ERA testing of antibiotics that provide 830 
appropriate limits for the protection of all prokaryotes and eukaryotes.  831 
A protection limit also needs to consider the extrapolation from the laboratory to 832 
the field. Previous authors have concluded that large safety factors are not 833 
considered necessary for extrapolation between the laboratory and field 834 
(Chapman et al., 1998). Indeed, biofilms in the field may provide resilience to 835 
chemical toxicity due to the protective nature of complex biofilm communities 836 
and extracellular substances (Harrison et al., 2007) and interspecies competition 837 
for resources may lower sensitivity to chemical contaminants (Rico et al., 2018). 838 
On the other hand, environmental conditions could significantly increase the 839 
sensitivity of bacteria to antibiotics due to chemical mixtures or as a result of 840 
different biotic and abiotic factors (e.g. competition, predation, temperature, pH 841 
(Rohr et al., 2016)). As such, in the absence of conclusive evidence 842 
demonstrating the safe concentrations in mixtures or in a variety of 843 
environmental conditions, it may be prudent to take a protective approach and 844 
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continue to include an assessment factor to compensate for this, as is required in 845 
some regulatory guidance (EFSA, 2013; TGD, 2003). Using an assessment factor 846 
with the HC5 or HC5(2.5) to establish a protection limit may appear to undermine 847 
the benefits of conducting a more accurate, reliable and robust SSD but more 848 
confidence can be applied to an empirically derived HC5/HC5(2.5) with a smaller 849 
assessment factor (of less than 10, although further investigation is required as 850 
these are still largely arbitrary) and for which error can be quantified. 851 
Furthermore, a HC5 has greater certainty compared with the current PNEC and 852 
thus a reduced likelihood of underestimating the PNEC where interspecies 853 
variability is high and overestimating the PNEC where interspecies variability is 854 
low. Finally, a SSD based on an ECx avoids the criticisms of the NOEC that is 855 
flawed and dependent of experimental design. 856 
The SSDs highlight that for the majority of MECs there is a limited general effect 857 
on cyanobacteria in the natural systems (potentially affected proportions of 858 
<1%) from all antibiotics based on the median MEC, which was based on data 859 
where the non-detects were excluded and thus a worse case scenario. However, 860 
60, 96 and 44% of cyanobacteria may be affected when exposed to the highest 861 
cefazolin, cefotaxime and ampicillin environmentally relevant MECs recorded in 862 
the UBA database (Umwelt bundesamt, 2018). Our analysis therefore suggests 863 
that there are some cyanobacterial communities that may be severely affected by 864 
antibiotic pollution with potential consequences on the ecosystem functions that 865 
they provide. Equally, however, our data suggests  that these effects are likely to 866 
be restricted to a small number of highly contaminated locations. In order to 867 
better estimate the risk of antibiotics in the environment, there is an urgent need 868 
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for more quantitative data on antibiotics in freshwater systems allowing for a 869 
better understanding of the distribution of MECs and more accurate estimations 870 
on possible associated  risks.  871 
Our results also show that a more comprehensive understanding of the effects of 872 
antibiotics upon prokaryotic diversity is needed for appropriate environmental 873 
protection. We argue that an ERA should include consideration of microbes that 874 
are known to play key roles in ecosystems function/services, such as nitrifying 875 
bacteria or sulphate-reducing bacteria as some of the organisms we may wish 876 
most to protect. Additionally, the effects on community structure and diversity 877 
should also be considered given that if a specific group of bacteria in a 878 
community increased or decreased in abundance due to antibiotic exposure, 879 
there may be significant consequences for the normal functioning of that 880 
community. 881 
5. Conclusions 882 
In this study we have used a microplate assay to assess the relative interspecies 883 
sensitivity of a range of cyanobacteria to the effects of seven antibiotics spanning 884 
three general MoAs. Our experimental data verify the findings of a meta-analysis 885 
of published literature (Le Page et al., 2017) where large interspecies sensitivity 886 
is observed and is influenced by the MoA. To our knowledge, we present the first 887 
environmentally relevant bacterial data for cefazolin and sulfamethazine.  888 
Although a PNEC established using an assessment factor of 10 on a NOEC 889 
appears to generally be protective when a sensitive species for that antibiotic is  890 
tested, it may cause protection limits to be either over- or under-protective 891 
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depending on the MoA. This approach may also result in  an increased level of 892 
uncertainty around the PNEC estimated. We conclude a probabilistic approach 893 
using an SSD and several bacterial assays that cover a wider range of bacterial 894 
diversity would better protect against the detrimental effects of antibiotics on 895 
the environment. These results therefore support previous recommendations by 896 
Le Page et al. (2017) and Brandt et al (2016) to widen the number of bacterial 897 
and cyanobacteria species tested. The data presented also suggest that 898 
cyanobacteria may not be a suitable group of bacteria for determining 899 
environmental risk to sulfonamides due to their insensitivity relative to other 900 
environmentally important taxa (e.g. other bacterial clades or macrophytes (Le 901 
Page et al., 2017)). Finally, we show that the highest recorded MECs in the 902 
literature may pose a significant threat to cyanobacteria populations. 903 
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